Read by QxMD icon Read

Omeprazol and gastric cancer

Laleh Mahmoudi, Shohreh Farshad, Mehrdad Seddigh, Paria Mahmoudi, Fardad Ejtehadi, Ramin Niknam
BACKGROUND: Helicobacter pylori (H pylori) is a common gastric pathogen which is associated with chronic gastritis, peptic ulcer, and gastric cancer. It has worldwide distribution with higher incidence in developing countries. Gemifloxacin is a fluoroquinolone antibiotic with documented in vitro activity against H pylori. Considering that there is no clinical data to verify gemifloxacin efficacy in H pylori eradication, this pilot clinical trial was designed. METHODS: This prospective pilot study was performed during February 2014 to February 2015...
October 2016: Medicine (Baltimore)
Carolina A Serrano, Miguel A Leon, Camila Palma, Macarena Vera, Caroll Hernandez, Paul R Harris
INTRODUCTION: Failure to eradicate Helicobacter pylori despite antibiotic treatment is generally attributed to increasing clarithromycin resistance conferred by point mutations in the 23S-rRNA gene or metronidazole resistance attributed to rdxA gene deletion in patients. Scarce data for pediatric population are available from developing countries. OBJECTIVES: To determine the presence of A2142G/C and A2143G mutations in the 23S-rRNA gene and/or rdxA gene deletion in a group of symptomatic H...
May 6, 2016: Journal of Pediatric Gastroenterology and Nutrition
Mohamed Alboraie, Motaz Saad, Jaber Al-Ali, Mohammad Malik, Noha Asem, Imre Schmidt, Ahmad A Alfadhli
BACKGROUND AND STUDY AIMS: Chronic infection caused by Helicobacter pylori (H. pylori) is associated with chronic gastritis, peptic ulcer disease, and gastric cancer. Eradication of H. pylori reduces morbidity of chronic gastritis and incidence of gastric cancer in high-risk population. We aimed at testing the efficacy of clarithromycin-based triple therapy and bismuth-based quadruple therapy for eradicating H. pylori in patients with chronic gastritis in Kuwait. PATIENTS AND METHODS: A total of 218 dyspeptic patients from different countries who were proved to have chronic gastritis by endoscopy and gastric biopsy were enroled...
September 2015: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
Mohammad Javad Ehsani-Ardakani, Meghdad Sedaghat, Gyti Eslami, Hamid Mohaghegh Shalmani
AIM: The aim of this study was to evaluate the Helicobacter pylori eradication in the group receiving standard -dose twice a day for two weeks and continue taking amoxicillin for 4 weeks. BACKGROUND: Helicobacter pylori is the major etiological cause of chronic gastritis, gastric and duodenal ulcers, gastric cancer and lymphoma. Therefore, patients should be treated after diagnosis of H. pylori infection. PATIENTS AND METHODS: A total of 66 consecutive patients with rapid urease test during endoscopy or biopsy positive for H...
2015: Gastroenterology and Hepatology From Bed to Bench
V E Khoronenko, M M Shemetova, O V Drozhzhina, V M Khomyakov, D D Sobolev
UNLABELLED: Despite a steady decline in the incidence in recent decades, gastric cancer remains one of the most frequent causes of death from cancer in the world. By the time of diagnosis the tumor process is locally advanced or generalized in nearly 70% of patients that reduces the possibility of radical surgical treatment. Peritoneal carcinomatosis is a one of the main causes of treatment failure. There patients need complex treatment with cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) to improve the quality and duration of life...
January 2015: Anesteziologiia i Reanimatologiia
Kai-feng Pan, Lian Zhang, Markus Gerhard, Jun-ling Ma, Wei-dong Liu, Kurt Ulm, Jian-xi Wang, Lei Zhang, Yang Zhang, Monther Bajbouj, Lan-fu Zhang, Ming Li, Michael Vieth, Rui-yong Liu, Michael Quante, Le-hua Wang, Stepan Suchanek, Tong Zhou, Wei-xiang Guan, Roland Schmid, Meinhard Classen, Wei-cheng You
OBJECTIVE: To clarify the full range of benefits and adverse consequences of Helicobacter pylori eradication as a strategy for gastric cancer prevention, the community-based intervention trial was launched in Linqu County, China. DESIGN: A total of 184,786 residents aged 25-54 years were enrolled in this trial and received (13)C-urea breath test. H. pylori positive participants were assigned into two groups, either receiving a 10-day quadruple anti-H. pylori treatment or lookalike placebos together with a single dosage of omeprazole and bismuth...
January 2016: Gut
Helge L Waldum, Per M Kleveland, Reidar Fossmark
Nordic research on physiology and pathophysiology of the upper gastrointestinal tract has flourished during the last 50 years. Swedish surgeons and physiologists were in the frontline of research on the regulation of gastric acid secretion. This research finally led to the development of omeprazole, the first proton pump inhibitor. When Swedish physiologists developed methods allowing the assessment of acid secretion in isolated oxyntic glands and isolated parietal cells, the understanding of mechanisms by which gastric acid secretion is regulated took a great step forward...
June 2015: Scandinavian Journal of Gastroenterology
Songhua Zhang, Dong Soo Lee, Rhiannon Morrissey, Jose R Aponte-Pieras, Arlin B Rogers, Steven F Moss
H. pylori infection causes gastritis, peptic ulcers and gastric cancer. Eradicating H. pylori prevents ulcers, but to what extent this prevents cancer remains unknown, especially if given after intestinal metaplasia has developed. H. pylori infected wild-type (WT) mice do not develop cancer, but mice lacking the tumor suppressor p27 do so, thus providing an experimental model of H. pylori-induced cancer. We infected p27-deficient mice with H. pylori strain SS1 at 6-8 weeks of age. Persistently H. pylori-infected WT C57BL/6 mice served as controls...
April 10, 2015: Cancer Letters
Ronald A Lubet, James M Scheiman, Ann Bode, Jonathan White, Lori Minasian, M Margaret Juliana, Daniel L Boring, Vernon E Steele, Clinton J Grubbs
The COX inhibitors (NSAID/Coxibs) are a major focus for the chemoprevention of cancer. The COX-2-specific inhibitors have progressed to clinical trials and have shown preventive efficacy in colon and skin cancers. However, they have significant adverse cardiovascular effects. Certain NSAIDs (e.g., naproxen) have a good cardiac profile, but can cause gastric toxicity. The present study examined protocols to reduce this toxicity of naproxen. Female Fischer-344 rats were treated weekly with the urinary bladder-specific carcinogen hydroxybutyl(butyl)nitrosamine (OH-BBN) for 8 weeks...
April 2015: Cancer Prevention Research
Takashi Kawai, Shin'ichi Takahashi, Hidekazu Suzuki, Hitoshi Sasaki, Akihito Nagahara, Daisuke Asaoka, Takeshi Matsuhisa, Tatsuhiro Masaoaka, Toshihiro Nishizawa, Masayuki Suzuki, Masayoshi Ito, Naoto Kurihara, Fumio Omata, Shigeaki Mizuno, Akira Torii, Kohei Kawakami, Toshifumi Ohkusa, Kengo Tokunaga, Tetsuya Mine, Nobuhiro Sakaki
BACKGROUND AND AIM: Helicobacter pylori (H. pylori) infection is a strong risk factor for the development of gastric cancer. In 2013, the Japanese government approved H. pylori eradication therapy in patients with chronic gastritis as well as peptic ulcer. However, the continuing decline in eradication rates for first-line H. pylori eradication therapies is an urgent problem. In this study, we investigated changes in the first-line eradication rate from 2001 to 2010. METHODS: Eradication rates for 7-day triple therapy [proton pump inhibitor (rabeprazole 20 mg, lansoprazole 60 mg, or omeprazole 40 mg)+amoxicillin 1500 mg + clarithromycin (CAM) 400 or 800 mg, daily] were collated from 14 hospitals in the Tokyo metropolitan area...
December 2014: Journal of Gastroenterology and Hepatology
Michael P Chu, Sunita Ghosh, Carole R Chambers, Naveen Basappa, Charles A Butts, Quincy Chu, David Fenton, Anil A Joy, Randeep Sangha, Michael Smylie, Michael B Sawyer
BACKGROUND: Erlotinib is a key therapy for advanced NSCLC. Concurrent AS therapy with TKIs might reduce TKI plasma levels. Because of gastroesophageal reflux disease prevalence, this retrospective analysis was undertaken to determine if coadministering erlotinib with AS therapy affected NSCLC outcomes. PATIENTS AND METHODS: Records of advanced NSCLC patients who received erlotinib from 2007 to 2012 at a large, centralized, cancer institution were retrospectively reviewed...
January 2015: Clinical Lung Cancer
Songhua Zhang, Dong Soo Lee, Rhiannon Morrissey, Jose R Aponte-Pieras, Arlin B Rogers, Steven F Moss
H. pylori infection causes gastritis, peptic ulcers and gastric cancer. Eradicating H. pylori prevents ulcers, but to what extent this prevents cancer remains unknown, especially if given after intestinal metaplasia has developed. H. pylori infected wild-type (WT) mice do not develop cancer, but mice lacking the tumor suppressor p27 do so, thus providing an experimental model of H. pylori-induced cancer. We infected p27-deficient mice with H. pylori strain SS1 at 6-8 weeks of age. Persistently H. pylori-infected WT C57BL/6 mice served as controls...
December 1, 2014: Cancer Letters
Kazuhide Higuchi, Toshihisa Takeuchi, Noriya Uedo, Yoji Takeuchi, Yuji Naito, Nobuaki Yagi, Kazunari Tominaga, Hirohisa Machida, Takashi Tamada, Yoshinori Morita, Shujiro Yazumi, Junichi Yamao, Mikitaka Iguchi, Takeshi Azuma
BACKGROUND: Endoscopic submucosal dissection (ESD) has been developed for early gastric cancer (EGC). Helicobacter pylori eradication therapy has been reported to have a preventive effect against metachronous recurrence of EGC after ESD. However, the efficacy and safety of eradication therapy on ESD-induced ulcer healing are not clear. In a randomized control study, we compared the standard therapy (8-week proton pump inhibitor) and eradication therapy combined with subsequent treatment with 7-week rebamipide for healing ESD-induced ulcers...
July 2015: Gastric Cancer
Aiping Tian, Ting Xu, Kaiyun Liu, Quanming Zou, Xiang Yan
BACKGROUND: Helicobacter pylori (H. pylori) infection could lead to most gastroduodenal diseases and is even identified as a carcinogen of gastric cancer. Total alkaloids of sophora alopecuroides (TASA) is widely used in herbal remedies to treat various infectious diseases, including stomach-associated diseases. This study is aimed at evaluating the antimicrobial activity of TASA on H. pylori-infected BALB/c mice mouse gastritis. METHODS: Totally 120 BALB/c mice were orally inoculated with H...
2014: Chinese Medical Journal
Wen-Qing Li, Jun-Ling Ma, Lian Zhang, Linda M Brown, Ji-You Li, Lin Shen, Kai-Feng Pan, Wei-Dong Liu, Yuanreng Hu, Zhong-Xiang Han, Susan Crystal-Mansour, David Pee, William J Blot, Joseph F Fraumeni, Wei-Cheng You, Mitchell H Gail
Among 2258 Helicobacter pylori-seropositive subjects randomly assigned to receive one-time H. pylori treatment with amoxicillin-omeprazole or its placebo, we evaluated the 15-year effect of treatment on gastric cancer incidence and mortality in subgroups defined by age, baseline gastric histopathology, and post-treatment infection status. We used conditional logistic and Cox regressions for covariable adjustments in incidence and mortality analyses, respectively. Treatment was associated with a statistically significant decrease in gastric cancer incidence (odds ratio = 0...
July 2014: Journal of the National Cancer Institute
Liya Zhou, Sanren Lin, Shigang Ding, Xuebiao Huang, Zhu Jin, Rongli Cui, Lingmei Meng, Yuan Li, Li Zhang, Changji Guo, Yan Xue, Xiu'e Yan, Jing Zhang
BACKGROUND: Helicobacter pylori (Hp) is a common and potentially curable cause of gastric mucosa lesion. This study investigated the relationship of Hp infection with histological changes in gastric mucosa and gastric cancer in Hp-positive patients compared with Hp-eradication patients followed up for ten years. METHODS: From an initial group of 1 006 adults, 552 Hp-positive subjects were randomly assigned to a treatment group (T; n = 276) or a placebo group (P; n = 276)...
2014: Chinese Medical Journal
Jeongmin Choi, Sang Gyun Kim, Hyuk Yoon, Jong Pil Im, Joo Sung Kim, Woo Ho Kim, Hyun Chae Jung
BACKGROUND & AIMS: It is not clear whether eradication of Helicobacter pylori infection reduces the risk for metachronous gastric carcinoma. We performed a prospective, randomized, open-label trial of the effects of H pylori eradication on the incidence of metachronous carcinoma after endoscopic resection of gastric tumors. METHODS: From April 2005 through February 2011 there were 901 consecutive patients with H pylori infection who had been treated with endoscopic resection for gastric dysplasia or cancer and who were assigned randomly to groups given therapy to eradicate the infection (n = 444) or no therapy (controls, n = 457)...
May 2014: Clinical Gastroenterology and Hepatology
Layli Eslami, Siavosh Nasseri-Moghaddam
BACKGROUND: Proton pump inhibitors (PPIs) are the most effective agents available for reducing acid secretion. They are used for medical treatment of various acid-related disorders. PPIs are used extensively and for extended periods of time in gastroesophageal reflux disease (GERD). A troublesome issue regarding maintenance therapy has been the propensity of PPI-treated patients to develop chronic atrophic gastritis while on therapy that could theoretically lead to an increased incidence of gastric cancer...
August 2013: Archives of Iranian Medicine
Wei Li, Su Zeng, Lu-Shan Yu, Quan Zhou
BACKGROUND: Omeprazole, a proton pump inhibitor (PPI), is widely used for the treatment of dyspepsia, peptic ulcer, gastroesophageal reflux disease, and functional dyspepsia. Polypharmacy is common in patients receiving omeprazole. Drug toxicity and treatment failure resulting from inappropriate combination therapy with omeprazole have been reported sporadically. Systematic review has not been available to address the pharmacokinetic drug-drug interaction (DDI) profile of omeprazole with adverse consequences, the factors determining the degree of DDI between omeprazole and comedication, and the corresponding clinical risk management...
2013: Therapeutics and Clinical Risk Management
Qiaoyin Zhang, Nianyu Huang, Junzhi Wang, Huajun Luo, Haibo He, Mingruo Ding, Wei-Qiao Deng, Kun Zou
Trametenolic acid B (TAB), the bioactive component in the Trametes lactinea (Berk.) Pat, was reported to possess cytotoxic activities and thrombin inhibiting effects. This study was performed to investigate the effects of TAB on H(+)/K(+)-ATPase and gastric cancer. The H(+)/K(+)-ATPase inhibitory activity was determined by gastric parietal cells. Compared to the normal control group, TAB (10, 20, 40 and 80 μg/mL) inhibited the H(+)/K(+)-ATPase activity by 15.97, 16.96, 24.86 and 16.25%, respectively. In the study, 36 Kunming mice were randomly divided into six groups: control, model, TAB-L (TAB, 5 mg/kg/day, i...
September 2013: Fitoterapia
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"